Race Oncology Ltd (ASX:RAC) has fielded “impressive” Phase 2 clinical trial results from its Acute Myeloid Leukaemia (AML) clinical trial. The interim clinical results are from an ongoing investigator-initiated Phase 2 trial of bisantrene in combination with fludarabine and clofarabine in…
Race Oncology (ASX:RAC) has announced positive interim clinical results from an ongoing investigator-initiated Phase II study of its core asset bisantrene in combination with fludarabine and clofarabine in R/R AML patients. Read more here.
Race Oncology Ltd (ASX:RAC) executive director Dr Pete Smith speaks with Proactive soon after announcing the company has initiated the toxicology and safety pharmacology studies required to support human clinical trials of its flagship bisantrene formulation for peripheral infusion, RC220. The company has…
Writing in The Australian, Stockhead reported on Race Oncology’s revised corporate strategy. They spoke to Race Oncology CEO and MD Damian Clarke-Bruce about how Race Oncology is working to put itself at the heart of cancer care. Read the full…
Race Oncology CEO and MD Damian Clarke-Bruce and Chief Medical Officer Dr Michelle Rashford talked shareholders through Race’s refreshed corporate strategy and answered their questions during a webinar last week. Watch the full webinar here.
Proactive Investors reported on Race Oncology’s revised corporate strategy, designed to maximise the commercial potential of bisantrene. See the full report here.
Proactive Investors reported on Race’s recent first half clinical programs update. Read the full story here.
Race Oncology is pleased to release a detailed commercial assessment of the market potential for Zantrene® as a cardio-protective agent or dual cardio-protective + anti-cancer in breast, endometrial and ovarian cancers.Key points from the research include: CEO and Managing Director,…
